

# Multiple Myeloma in Argetina

Supporting early and equitable access  
to care to improve patient outcomes


Sponsored by



**45.5m**  
Population 2022<sup>1</sup>



**7%**  
Government funding  
allocated to health, as  
a % of GDP<sup>2</sup>




11% of the population has > 1 one type of coverage




**37.4%**  
of total expenditure on  
health care comes from  
private sources<sup>4</sup>

## What is multiple myeloma?



It is an incurable blood cancer that typically **originates in the bone marrow.**




Accounts for 10% of all blood cancers and is the **2<sup>nd</sup> most common blood cancer globally.**



It is **more common among older adults.** The median age of multiple myeloma patients at presentation in Argentina is 63 years.<sup>5</sup>

## Signs and symptoms


Prevalence among myeloma patients in Argentina.<sup>6</sup>





## Burden of Myeloma on the rise


Cases and deaths in Argentina are projected to double by 2040.<sup>7</sup>



## Access to care




Patients are diagnosed with advanced disease (**stage 3**).<sup>8</sup>



Patients with multiple myeloma experience a high burden of co-morbidities. **72% of patients had co-morbidities at the time of diagnosis.**<sup>8</sup>



is the **average time between a cancer treatment** receiving regulatory approval in Argentina to the treatment being available to patients through the public health system.<sup>9</sup>




of patients  $\geq 60$  years were **hospitalized within a year of their myeloma diagnosis.**<sup>10</sup>

## Survival


A study of 1293 patients with myeloma across Latin America highlighted **stark differences in outcomes** between patients receiving care in the public and private sectors.

The 5-year overall survival rate in patients treated in the private sector was almost twice the rate of those treated in the public sector.<sup>11</sup>

**5-year overall survival rate among patients in the private sector**  
80%



**5-year overall survival rate among patients in the public sector**  
46%



1 Economist Intelligence Unit. Data Tool [Internet]. London: The Economist Intelligence Unit. Available from: <https://data.eiu.com/>.  
 2 World Health Organization. Global Health Expenditure database - Government schemes and compulsory contributory health care financing schemes % Gross domestic product (GDP) [Internet]. Available from: <https://apps.who.int/nha/database/Select/Indicators/en>.  
 3 Argentine Congressional Budget Office (OPC) Evaluation Policies. [Internet]. Argentina. Argentine Congressional Budget Office. Available from: <https://www.opc.gob.ar/evaluacion-politicas-de-gobierno/caracterizacion-del-sistema-de-salud-argentino/>.  
 4 World Health Organization. Global Health Expenditure database - Domestic private health expenditure (% of current health expenditure) [Internet]. Available from: <https://apps.who.int/nha/database/Select/Indicators/en>.  
 5 de Moraes Hungria VM, Gaiolla R, Cardenas KG, et al. MYLACRE Study: Demographic and clinical characteristics of Multiple Myeloma patients in Latin America. Presented at HEMO, October 28, 2022; São Paulo, São Paulo, Brazil.  
 6 de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016. British journal of haematology. 2020;188(3):383-93.  
 7 International Agency for Research on Cancer. Cancer Tomorrow [Internet]. France: Global Cancer Observatory. Available from: <https://gco.iarc.fr/tomorrow/en/>.  
 8 de Moraes Hungria VT, Chiattoni C, Pavlovsky M, et al. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol. 2019;(5):1-19.  
 9 FIFARMA. Patients W.A.L.T. Indicator 2022 Survey [Internet]. Available from: [https://fifarma.org/wp-content/uploads/2022/12/FIFARMA-WAIT-Indicator-2022\\_Report\\_vFinal-30SEP2022-4.pdf](https://fifarma.org/wp-content/uploads/2022/12/FIFARMA-WAIT-Indicator-2022_Report_vFinal-30SEP2022-4.pdf).  
 10 Pinelli M, Amigo C, Alvarado CA, Figueroa R, Bucheli E. Multiple myeloma: Burden of disease analysis in some countries of Latin America. Oncologia Clinica. 2018;23:27-36.  
 11 Peña C, Riva E, Schutz N, et al. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leuk Lymphoma. 2020;61(13):3112-9.